Stephen Uden, Chief Executive Officer and Director of Rallybio Corp, filed a Form 4 on October 29, 2026, disclosing the exercise of stock options and acquisition of common stock on October 27, 2026.

Key Highlights

  • Transaction date: October 27, 2026, involving 33,244 shares of Rallybio Corp common stock acquired via option exercise (transaction code M).
  • Exercise price: $6.08 per share for the option converted to common stock.
  • Resulting ownership: Stephen Uden directly holds 148,864 shares of common stock following the reported transaction.
  • Option disposition: The 33,244 underlying options were fully disposed of, leaving 0 derivative securities beneficially owned following the transaction.
  • Plan origin: The option was granted under the company's 2021 Equity Incentive Plan, vesting in 48 equal monthly installments until fully vested on February 14, 2029.
  • Price of derivative security: The derivative security was disposed of at a price of $0.00.

Details of Stephen Uden's Option Exercise at Rallybio Corp

According to the Form 4 filed with the SEC on October 29, 2026, Stephen Uden, who serves as both Chief Executive Officer and Director of Rallybio Corp (NASDAQ:RLYB), reported a transaction coded "M," indicating the exercise of an option to acquire common stock. On October 27, 2026, Uden acquired 33,244 shares of common stock at a price of $6.08 per share through this exercise. Following the transaction, his direct beneficial ownership of common stock stands at 148,864 shares, as reported in the filing.

The filing also discloses the corresponding disposition of the derivative security. The option, which carried a conversion or exercise price of $6.08, had an expiration date of February 14, 2035, and was originally granted under the company's 2021 Equity Incentive Plan. The filing states the option "vests in 48 equal monthly installments until fully vested on February 14, 2029." Following the reported exercise, the number of these derivative securities beneficially owned by Uden is listed as 0, with a disposition price of $0.00.

The Form 4 was filed by Jonathan Lieber as Attorney-in-Fact on behalf of Stephen Uden. All reported securities are held directly. No indirect beneficial ownership was reported in connection with this transaction.

What Was Disclosed

Stephen Uden, CEO and Director of Rallybio Corp, disclosed the exercise of 33,244 stock options at $6.08 per share on October 27, 2026, resulting in direct ownership of 148,864 shares of common stock and zero remaining derivative securities from this option grant.